Lisa Moorehead

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

Eric Lawitz, Daniel Gruener, John M. Hill et al. · Journal of Hepatology · 2012 · 158 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Zidovudine use but not weight‐based ribavirin dosing impacts anaemia during HCV treatment in HIV‐infected persons

D. Alvarez, Douglas T. Dieterich, Norbert Bräu et al. · Journal of Viral Hepatitis · 2006 · 123 citations

Pharmacy, Pharmacotherapy, Clinical Pharmacology +13

Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis with <i>Pseudomonas</i> Airway Infection

Bruce C. Trapnell, Susanna A. McColley, Dana G. Kissner et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 114 citations · Full text

Pharmacy, Pharmacotherapy, Respiratory Therapy +13

Safety, Pharmacokinetics and Pharmacodynamics of Gs-9620, An Oral Toll-Like Receptor 7 Agonist

Uri Lopatin, Grushenka H.I. Wolfgang, Daniel B. Tumas et al. · Antiviral Therapy · 2013 · 56 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development

Jim Zheng, Jingyu Zhang, Raju Subramanian et al. · Drug Metabolism and Disposition · 2018 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13